COCM
AMRX icon

Charter Oak Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Charter Oak Capital Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25
Closed – – 193
2022
Q2 		$0 Hold
25
– – ﹤0.01% 909
2022
Q1 		$0 Hold
25
– – ﹤0.01% 956
2021
Q4 		$0 Buy
+25
New +$125 ﹤0.01% 846

Other funds holding AMRX

FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charter Oak Capital Management's AMRX Position: Q3 2022 in Review

Charter Oak Capital Management sold out of Amneal Pharmaceuticals (AMRX) in Q3 2022, closing a stake of 25 shares.

Charter Oak Capital Management first reported a position in AMRX in Q4 2021 and held it in 3 quarters. The position peaked at $0 in Q2 2022. 154 funds tracked by Wall St. Rank hold AMRX as of Q3 2022.

  • Charter Oak Capital Management reported no remaining Amneal Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Charter Oak Capital Management sold 25 Amneal Pharmaceuticals shares in Q3 2022.
  • Charter Oak Capital Management first reported a position in Amneal Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • Charter Oak Capital Management's Amneal Pharmaceuticals position peaked at $0 in Q2 2022.
  • 154 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.